Geratherm Medical AG (DE:GME)
XETRA:GME
Want to see DE:GME full AI Analyst Report?
Top Page
Geratherm Medical
(XETRA:GME)
Select Model
Select Model
Rating:56Neutral
Price Target:
€3.00
▲(4.90% Upside)
Action:Reiterated
Date:06/14/26
The score is primarily supported by a conservatively financed balance sheet and recent positive cash generation, but it is held back by the 2025 return to losses and weak technical positioning (trading below key moving averages with slightly negative MACD). Valuation is reasonable with a mid P/E and a solid dividend yield.
Positive Factors
Conservative balance sheet
Low leverage and a sizable equity base provide structural financial resilience. With debt reduced since 2020–2022, the company has balance-sheet flexibility to absorb cyclical earnings shocks, support working capital, fund targeted investment, or sustain dividends during short-term profit weakness.
Negative Factors
Return to losses in 2025
The swing back to operating losses and negative net margin in 2025 weakens internal funding capacity and undermines sustained profitability. Persistent losses could erode investor optionality, force cost reductions or lower R&D, and impair long-term returns on the company’s capital base.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage and a sizable equity base provide structural financial resilience. With debt reduced since 2020–2022, the company has balance-sheet flexibility to absorb cyclical earnings shocks, support working capital, fund targeted investment, or sustain dividends during short-term profit weakness.
Read all positive factors
Geratherm Medical (GME) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€14.86M
Dividend Yield3.46%
Average Volume (3M)4.33K
Price to Earnings (P/E)16.4
Beta (1Y)0.65
Revenue Growth6.33%
EPS Growth-216.17%
CountryDE
Employees179
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.28
Shares Outstanding5,444,998
10 Day Avg. Volume3,658
30 Day Avg. Volume4,334
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.80
Price to Sales (P/S)1.05
P/FCF Ratio12.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)€16.50M
Geratherm Medical Business Overview & Revenue Model
Company Description
Geratherm Medical AG, a German-based medical technology enterprise, organizes its operations across four primary divisions: Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems. The Healthcare Diagnostic unit offers a ran...
How the Company Makes Money
null...
Geratherm Medical Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
74
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.29M | 14.86M | 20.43M | 20.96M | 25.85M | 24.64M |
| Gross Profit | 5.96M | 2.37M | 12.78M | 6.27M | 6.38M | 16.32M |
| EBITDA | -1.94M | -154.63K | 2.95M | 4.18M | 3.37M | 2.20M |
| Net Income | 1.75M | -818.99K | 705.17K | 1.11M | 1.02M | 122.23K |
Balance Sheet | ||||||
| Total Assets | 27.53M | 26.00M | 28.54M | 35.72M | 38.38M | 34.56M |
| Cash, Cash Equivalents and Short-Term Investments | 9.61M | 9.26M | 9.64M | 7.74M | 10.89M | 6.47M |
| Total Debt | 2.62M | 2.48M | 3.28M | 7.23M | 9.29M | 9.32M |
| Total Liabilities | 6.95M | 6.55M | 7.71M | 13.11M | 16.15M | 15.93M |
| Stockholders Equity | 20.83M | 19.66M | 21.02M | 22.33M | 22.34M | 18.52M |
Cash Flow | ||||||
| Free Cash Flow | 2.68M | 1.22M | 1.23M | -212.00K | -133.00K | -353.00K |
| Operating Cash Flow | 2.79M | 1.39M | 1.87M | 1.43M | 2.61M | 917.00K |
| Investing Cash Flow | 3.89M | -328.00K | 3.82M | -2.09M | -767.00K | 3.00K |
| Financing Cash Flow | -2.43M | -1.31M | -2.69M | -3.09M | 4.35M | -3.52M |
Geratherm Medical Technical Analysis
Negative
2.86
Price Trends
2.77
Negative
2.76
Negative
3.12
Negative
Market Momentum
-0.01
Positive
46.18
Neutral
43.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:GME, the sentiment is Negative. The current price of 2.86 is above the 20-day moving average (MA) of 2.77, above the 50-day MA of 2.77, and below the 200-day MA of 3.12, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 46.18 is Neutral, neither overbought nor oversold. The STOCH value of 43.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:GME.
Geratherm Medical Peers Comparison
UnderperformOutperform
Sector (55)
DE:GME
Geratherm Medical
2.73
-0.51
-15.74%
DE:AAQ1
aap Implantate
1.81
0.35
23.97%
DE:B8FK
Biofrontera
2.35
-0.02
-0.84%
DE:SBX
SynBiotic SE
1.43
-1.73
-54.62%
DE:BIG1
Bio-Gate AG
0.64
-0.36
-36.00%
DE:E8X
elexxion AG
0.07
-0.13
-65.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.